Reprise par OPM de l’intégralité des droits du programme OPM-201 et du portefeuille de brevets associé Confirmation de l’innocuité de la...
Finalization of the study report on the double-blind, placebo-controlled Phase 1 trial of OPM-101 in 104 healthy volunteers (HV) who received...
Présentation par le Professeur Laurent Peyrin-Biroulet (M.D., PhD Professeur de gastroentérologie au CHRU de Nancy) et Bruno Robin (PharmD...
OPM-101 conclut positivement sa Phase 1 volontaires sains permettant de prévoir le démarrage d'un essai clinique de Phase 1b/2a, fin 2024 début...
End of double-blind, placebo-controlled phase 1 trial with OPM-101: 104 healthy volunteers (VS) participated in this trial designed to assess...
Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM), entreprise biopharmaceutique spécialisée en...
Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM) (Paris:ALOPM), entreprise biopharmaceutique...
Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads